Loading...
•
Jun 30, 2024
Exact Sciences Q2 2024 Earnings Report
Achieved record results, screened over 1 million people with Cologuard, and raised adjusted EBITDA guidance.
Key Takeaways
Exact Sciences Corp. announced strong second-quarter results, with a 12% increase in total revenue to $699 million. The company screened over 1 million people with Cologuard for the first time in a quarter and advanced its pipeline. Full-year revenue guidance was maintained, and adjusted EBITDA guidance was raised.
Total second quarter revenue was $699 million, a 12% increase year-over-year.
Screening revenue reached $532 million, a 15% increase year-over-year.
Precision Oncology revenue was $168 million, a 7% increase year-over-year.
Adjusted EBITDA was $110 million, with an adjusted EBITDA margin of 16%.
Revenue by Segment
Forward Guidance
The company maintained its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...